Evaluating the Importance of Independent Action in ADC Combination Trials
Time: 9:00 am
day: day 2- am
Details:
- Highlighting how immuno oncology drugs are failing at an unprecedented rate -perhaps because too much reliance has been placed on preclinical thinking about synergy
- Based on the mathematics of independent action, synergy has not been seen in any immune oncology registration trials to date
- To progress the development of combinations of ADC and PD-1 immune checkpoint inhibitors the field must adapt more rigorous mathematic thinking about combination results
